OBJECTIVE:To identify the main active components and targets of Huashi Xingyu Qingre recipe(化湿行淤清热方,HXQR)and to investigate its mechanism in the treatment of oral lichen planus(OLP).METHODS:The Traditional Chin...OBJECTIVE:To identify the main active components and targets of Huashi Xingyu Qingre recipe(化湿行淤清热方,HXQR)and to investigate its mechanism in the treatment of oral lichen planus(OLP).METHODS:The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was searched to identify the active ingredients and corresponding targets of HXQR.Disease genes were obtained from the Gene Cards database,and a“drugdisease regulatory network”was constructed using Cytoscape software and PERL programming language.The STRING database was used to build a protein-protein interaction network.Gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)terms were analyzed using R software with a Bioconducter plugin.Finally,the results and the efficacy of HXQR in treating OLP were validated in a clinical trial that included enzyme-linked immunosorbent assay(ELISA)testing and observations of the post-treatment changes in clinical symptoms.RESULTS:HXQR contained 167 active components and 261 targets,with 391 disease targets.The intersection of these two categories in a Venn diagram revealed 57 drugdisease common targets.A compound-target network was constructed and revealed that the six key pharmaceutical ingredients of HXQR were quercetin,luteolin,wogonin,kaempferol,beta-carotene,and baicalein.The protein-protein interaction network mainly involved core proteins such as ALB,interleukin-6,and AKT1.Drug-disease common targets were enriched in 1628 GO terms and 117 KEGG terms,mainly involving inflammatory responses,viral infections,and tumorrelated pathways.ELISA testing indicated that HXQR inhibited the tumor necrosis factor(TNF)signaling pathway by reducing the expression of interleukin-6,matrix metalloproteinase-9,and intercellular adhesion molecule-1.The clinical symptoms of the patients with OLP were significantly improved after 8 weeks of treatment with HXQR.CONCLUSION:HXQR treats OLP by regulating the TNF signaling pathway,resulting in a marked treatment effect with few adverse effects.展开更多
目的:探讨化痰行瘀通腑汤保留灌肠联合特布他林治疗慢性阻塞性肺病急性加重期(AECOPD)痰热壅肺型患者的效果观察。方法:选取2014年1月至2016年1月廊坊市中医医院收治的AECOPD患者100例作为研究对象,按照随机数字表法分为对照组与观察组...目的:探讨化痰行瘀通腑汤保留灌肠联合特布他林治疗慢性阻塞性肺病急性加重期(AECOPD)痰热壅肺型患者的效果观察。方法:选取2014年1月至2016年1月廊坊市中医医院收治的AECOPD患者100例作为研究对象,按照随机数字表法分为对照组与观察组,每组50例。对照组采用特布他林治疗,观察组采用化痰行瘀通腑汤保留灌肠联合特布他林治疗。比较2组患者临床疗效、临床症状和体征、肺通气功能指标、6 min步行试验(6 MWT)、血清生化指标、肠道屏障功能指标、中医症状积分变化及不良反应发生率。结果:观察组的治疗总有效率(92.0%)显著高于对照组(74.0%)( P <0.05)。观察组喘息缓解时间、咳嗽消失时间、喘鸣音消失时间、湿罗音消失时间均显著短于对照组( P <0.05)。观察组FEV1、FVC、PEF、FEV1/FVC、6MWT均显著高于对照组( P <0.05)。观察组WBC、N%、IL-6、LTB4均显著低于对照组( P < 0.05)。观察组血清DAO、IFABP、LPS均显著低于对照组( P <0.05)。观察组中医症状积分变化高于对照组( P <0.05)。2组患者在治疗过程中均未发生明显不良反应。结论:非化痰行瘀通腑汤保留灌肠联合特布他林可显著改善AECOPD患者临床症状、肺通气功能、肠道屏障功能,且不良反应少。展开更多
基金Supported by Proteomics Study on Differential Protein of Oral Lichen Planus and Chinese Medicine Intervention of Huashi Xingyu Qingre recipe(No.81273813)Effect of Huashi Xingyu Qingre recipe on Differential Protein Expression Of Oral Lichen Planus(No.2011013)+3 种基金the Project of National Cancer Center Climbing Fund(No.NCC201803B006)the Project of Health Department Research Fund of Hebei Province(No.20170691)Scientific Research Project of TCM administration in Hebei Province(No.2018138)Governmentfunded Outstanding Talents Project in 2020(No.2704016)。
文摘OBJECTIVE:To identify the main active components and targets of Huashi Xingyu Qingre recipe(化湿行淤清热方,HXQR)and to investigate its mechanism in the treatment of oral lichen planus(OLP).METHODS:The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was searched to identify the active ingredients and corresponding targets of HXQR.Disease genes were obtained from the Gene Cards database,and a“drugdisease regulatory network”was constructed using Cytoscape software and PERL programming language.The STRING database was used to build a protein-protein interaction network.Gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)terms were analyzed using R software with a Bioconducter plugin.Finally,the results and the efficacy of HXQR in treating OLP were validated in a clinical trial that included enzyme-linked immunosorbent assay(ELISA)testing and observations of the post-treatment changes in clinical symptoms.RESULTS:HXQR contained 167 active components and 261 targets,with 391 disease targets.The intersection of these two categories in a Venn diagram revealed 57 drugdisease common targets.A compound-target network was constructed and revealed that the six key pharmaceutical ingredients of HXQR were quercetin,luteolin,wogonin,kaempferol,beta-carotene,and baicalein.The protein-protein interaction network mainly involved core proteins such as ALB,interleukin-6,and AKT1.Drug-disease common targets were enriched in 1628 GO terms and 117 KEGG terms,mainly involving inflammatory responses,viral infections,and tumorrelated pathways.ELISA testing indicated that HXQR inhibited the tumor necrosis factor(TNF)signaling pathway by reducing the expression of interleukin-6,matrix metalloproteinase-9,and intercellular adhesion molecule-1.The clinical symptoms of the patients with OLP were significantly improved after 8 weeks of treatment with HXQR.CONCLUSION:HXQR treats OLP by regulating the TNF signaling pathway,resulting in a marked treatment effect with few adverse effects.
文摘目的:探讨化痰行瘀通腑汤保留灌肠联合特布他林治疗慢性阻塞性肺病急性加重期(AECOPD)痰热壅肺型患者的效果观察。方法:选取2014年1月至2016年1月廊坊市中医医院收治的AECOPD患者100例作为研究对象,按照随机数字表法分为对照组与观察组,每组50例。对照组采用特布他林治疗,观察组采用化痰行瘀通腑汤保留灌肠联合特布他林治疗。比较2组患者临床疗效、临床症状和体征、肺通气功能指标、6 min步行试验(6 MWT)、血清生化指标、肠道屏障功能指标、中医症状积分变化及不良反应发生率。结果:观察组的治疗总有效率(92.0%)显著高于对照组(74.0%)( P <0.05)。观察组喘息缓解时间、咳嗽消失时间、喘鸣音消失时间、湿罗音消失时间均显著短于对照组( P <0.05)。观察组FEV1、FVC、PEF、FEV1/FVC、6MWT均显著高于对照组( P <0.05)。观察组WBC、N%、IL-6、LTB4均显著低于对照组( P < 0.05)。观察组血清DAO、IFABP、LPS均显著低于对照组( P <0.05)。观察组中医症状积分变化高于对照组( P <0.05)。2组患者在治疗过程中均未发生明显不良反应。结论:非化痰行瘀通腑汤保留灌肠联合特布他林可显著改善AECOPD患者临床症状、肺通气功能、肠道屏障功能,且不良反应少。
